IP Library › Granted Patent US 8,507,675
Granted Patent B2
US 8,507,675 · App. 13/241,041 · Granted Aug 13, 2013

Compositions and methods for inhibition of the JAK pathway

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,507,675
App. No.
13/241,041
Granted
Aug 13, 2013
Kind
B2
Abstract

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

Claims (1)

1. A compound, or pharmaceutically acceptable salt thereof, wherein the compound is 5-(2-(3-methoxy-4,5-dimethylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-one.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2011
From: LI, HUI; HECKRODT, THILO J.; CHEN, YAN; TAYLOR, VANESSA; SINGH, RAJINDER; DING, PINGYU; YEN, ROSE
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 027214/0064 →